tradingkey.logo

BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide

ReutersMar 3, 2025 12:19 PM

- Takeda Pharmaceutical 4502.T:

  • PROTAGONIST AND TAKEDA ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VERIFY STUDY OF RUSFERTIDE IN PATIENTS WITH POLYCYTHEMIA VERA

  • PROTAGONIST THERAPEUTICS INC - STUDY MEETS PRIMARY ENDPOINT WITH HIGHER CLINICAL RESPONDERS ON RUSFERTIDE

  • PROTAGONIST THERAPEUTICS INC - ALL FOUR KEY SECONDARY ENDPOINTS MET IN VERIFY STUDY

  • PROTAGONIST THERAPEUTICS INC - RUSFERTIDE GENERALLY WELL TOLERATED WITH NO NEW SAFETY FINDINGS

  • PROTAGONIST THERAPEUTICS INC - IMPACT ON TAKEDA'S FY2024 FINANCIAL RESULTS IS IMMATERIAL

Source text: ID:nBwbPzjCsa

Further company coverage: 4502.T

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI